Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects

• Marta L Capone, Stefania Tacconelli, +7 authors Paola Patrignani
• Circulation
• 2004

BACKGROUND The current controversy on the potential cardioprotective effect of naproxen prompted us to evaluate the extent and duration of platelet, monocyte, and vascular cyclooxygenase (COX)… (More)

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects.

• Marta L Capone, Maria Gina Sciulli, +6 authors Paola Patrignani
• Journal of the American College of Cardiology
• 2005

OBJECTIVES We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin and naproxen. BACKGROUND The uncertainty of cardioprotection by naproxen has encouraged its… (More)

Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.

• Giulia Renda, Stefania Tacconelli, +11 authors Paola Patrignani
• Clinical pharmacology and therapeutics
• 2006

BACKGROUND AND OBJECTIVE We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1… (More)

Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina.

• Eduardo Luis López, María Marta Contrini, +6 authors Thomas G. Cleary
• The Pediatric infectious disease journal
• 1995

Hemolytic uremic syndrome (HUS) is thought to be a vascular endothelial injury disease. The mechanism of injury is unknown although verocytotoxins (Shiga-like toxins (SLTs)) are known to be… (More)

Platelet activation in patients with colorectal cancer.

• Maria Gina Sciulli, Paola Filabozzi, +6 authors Paola Patrignani
• Prostaglandins, leukotrienes, and essential fatty…
• 2005

Aspirin may reduce the risk of colorectal neoplasia at doses similar to those recommended for the prevention of cardiovascular disease. Thus, we aimed to address whether enhanced platelet activation,… (More)

Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea.

• Eduardo Luis López, María Marta Contrini, +6 authors Thomas G. Cleary
• The Journal of pediatrics
• 1995

Argentina has an exceptionally high frequency of hemolytic-uremic syndrome (HUS). We sought to define prospectively the role of verocytotoxins (Shiga-like toxins [SLTs]) in 254 Argentinean children… (More)

L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency.

• Joaquín Lado-Abeal, Marilena Grana, Corsino Rey, José Cabezas-Cerrato
• Clinical endocrinology
• 1998

OBJECTIVE There is abundant histological and physiological evidence that serotonin plays a role in the regulation of LH secretion in rats. Studies in human subjects have been few, but their results… (More)

Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients.

• Mario Di Gioacchino, Nicola Verna, +9 authors Theoharis C Theoharides
• International journal of immunopathology and…
• 2002

RANTES plays a crucial role in cell recruitment in allergic inflammation. We investigated the pharmacological modulation of RANTES release in cultured peripheral blood mononuclear cells obtained from… (More)

Long-term administration of pulsatile gonadotropin-releasing hormone for exploration of pituitary functionality in amenorrheic patients.

• Marilena Grana, Jordan Liz, J Mieza, A Stockem Novo, J. Luelmo Aguilar
• Gynecological endocrinology : the official…
• 1997

Differentiation between hypothalamic and pituitary amenorrhea is generally based on the luteinizing hormone-releasing hormone (LHRH) test (whether as a single dose, two consecutive doses, or… (More)

Pefloxacin in the antibacterial treatment of immunodepressed patients.

• Aurelio Cajozzo, Rosa Carbone, +6 authors Franco Dammacco
• Journal of chemotherapy
• 1990

Pefloxacin 800 to 1200 mg daily was given for 3 to 20 days, orally or intravenously, to 84 immunocompromised patients. Five patients dropped out because of side effects and 2 for other causes.… (More)

• ‹
• 1
• 2
• ›